Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 1-Year Low – Should You Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) hit a new 52-week low during trading on Wednesday . The company traded as low as $20.00 and last traded at $20.8110, with a volume of 53021 shares trading hands. The stock had previously closed at $20.78.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. Finally, UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Chugai Pharmaceutical presently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The firm has a market cap of $68.33 billion, a price-to-earnings ratio of 22.57 and a beta of 0.59. The business’s 50-day moving average price is $21.78 and its two-hundred day moving average price is $24.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.The company had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. As a group, sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.